Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032
세계의 텔미사르탄 시장 규모는 2023년 37억 달러에 달했습니다. 앞으로 IMARC Group은 예측 기간 동안 2.7%의 복합 연간 성장률(CAGR)을 보일 전망이며, 2032년에는 48억 달러에 달할 것으로 예측했습니다.
텔미사르탄은 비펩티드성 안지오텐신 수용체 차단제(ARB)로 고혈압과 심혈관 장애의 치료에 처방약으로 사용됩니다. 텔미사르탄은 정제와 경구유 현탁액의 2유형가 있으며, 효과를 높이기 위해 다른 약제와 병용됩니다. 강압 작용을 나타내고, 체내의 알도스테론 생산을 저해함으로써, 나트륨과 수분의 흡수를 감소시켜, 혈압을 저하시킵니다. 또한, 텔미사르탄은 혈관을 이완시켜 신장 기능을 촉진합니다. 그러나 현기증, 흔들림, 기침, 부비동 통증 등 다양한 부작용을 일으킬 수 있습니다.
텔미사르탄 시장 동향
세계의 제약 업계의 현저한 성장은 시장의 밝은 전망을 창출하는 중요한 요소 중 하나입니다. 또한, 고혈압, 당뇨병 및 다양한 신장 관련 질환의 유병률 증가가 시장 성장을 뒷받침하고 있습니다. Termisartan은 인슐린 감작 유전자를 변경하고 포도당과 지질의 대사를 조절하는 효과가 입증되었으며 만성 당뇨병 성 신장 질환과 앉기 쉬운 생활 습관으로 인한 기타 질병 관리에 도움이 됩니다. 제약 제조업체는 또한 고혈압 및 심혈관 질환에 대한 비용 효과적인 치료를 제공하기 위해 Termisartan 약물의 제네릭 버전을 출시합니다. 게다가 제약 제조업체는 당뇨병성 신증의 치료를 위한 첨단 텔미사르탄약의 연구개발(R&D)에 상당한 투자를 하고 있으며, 이것도 시장의 성장에 기여하고 있습니다. 기타, 노인 인구 증가나 의료 인프라의 대폭적인 개선 등이 시장을 더욱 견인할 것으로 예상됩니다.
이 보고서에서 다루는 주요 질문
- 세계의 텔미사르탄 시장은 지금까지 어떻게 추이해, 향후 어떻게 추이해 갈 것인가?
- COVID-19는 세계의 텔미사르탄 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 적응증별 시장 분석은?
- 유통채널별 시장 분석은?
- 업계의 밸류체인의 다양한 단계는?
- 업계의 주요 촉진요인과 도전은 무엇인가?
- 세계의 텔미사르탄 시장의 구조와 주요 진출기업은?
- 업계 경쟁도는?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 텔미사르탄 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 적응증별
제7장 시장 분석 : 유통채널별
제8장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 진입업자의 위협
- 대체품의 위협
제12장 가격 분석
제13장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abbott Laboratories
- Aurobindo Pharma USA
- Boehringer Ingelheim International GmbH
- Cipla Limited
- Hikma Pharmaceuticals plc
- Jubilant Cadista Pharmaceutical
- Sanofi SA
- Solco Healthcare(Prinston Pharmaceutical Inc.)
- Torrent Pharmaceuticals Ltd
BJH
The global telmisartan market size reached US$ 3.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.7% during 2024-2032.
Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.
Telmisartan Market Trends:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and distribution channel.
Breakup by Indication:
Hypertension
Cardiovascular Risk Reduction
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.
Key Questions Answered in This Report:
- How has the global telmisartan market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global telmisartan market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global telmisartan market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Telmisartan Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Indication
- 6.1 Hypertension
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cardiovascular Risk Reduction
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Drug Stores and Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Stores
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Aurobindo Pharma USA
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Boehringer Ingelheim International GmbH
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Cipla Limited
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Hikma Pharmaceuticals plc
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Jubilant Cadista Pharmaceutical
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Sanofi S.A.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Torrent Pharmaceuticals Ltd
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
